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Systemic lupus erythematosus is a chronic autoimmune disease, and recent findings have further strengthened the critical role of SLE-related immune dysregulation and metabolic disturbances in promoting accelerated CV disease. [2] [3] Moreover, RHR and markers of SLGI such as C-reactive protein (CRP), fibrinogen, and erythrocyte sedimentation rate (ESR) were shown to be associated with arterial stiffness and inflammation and these factors also strongly predispose to CV disease and all-cause mortality. [4] [5] [6] In previous studies, it has been shown that the levels of CRP, fibrinogen, and ESR were significantly higher in infectious diseases. 7 However, Vargas-Hitos et al 1 did not mention whether acute or chronic infectious disease was the exclusion criterion in their study. Besides, how did the authors ensure the exclusion of infection in the presence of very high CRP and ESR levels?
Another important issue, many easily available and reliable inflammatory and oxidative biomarkers such as white blood cell, neutrophil, lymphocyte, monocyte, platelet, mean platelet volume, and red cell distribution width have been demonstrated to be independent risk factors and prognostic markers for both inflammatory and CV disease. [8] [9] [10] Therefore, the authors should have provided details about these biochemical laboratory parameters, clinical data, or imaging tools.
As a final comment, it is crucial to know the SLE Disease Activity Index and the rates of anti-inflammatory or immunosuppression medication usage between the study groups for interpretation of the study findings. However, there is also no any data regarding this information in the study. 
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